Results 51 to 60 of about 13,550 (188)

German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant Pseudomonas aeruginosa Isolates Using a Commercially Available Broth Microdilution Assay

Antibiotics, 2022
Multidrug resistance is an emerging healthcare issue, especially concerning Pseudomonas aeruginosa. In this multicenter study, P. aeruginosa isolates with resistance against meropenem detected by routine methods were collected and tested for ...
Jana Manzke, Raphael Stauf, Bernd Neumann, Ernst Molitor, Gunnar Hischebeth, Michaela Simon, Jonathan Jantsch, Jürgen Rödel, Sören L. Becker, Alexander Halfmann, Thomas A. Wichelhaus, Michael Hogardt, Annerose Serr, Christina Hess, Andreas F. Wendel, Ekkehard Siegel, Holger Rohde, Stefan Zimmermann, Jörg Steinmann   +18 more
doaj   +1 more source

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase

, 2023
Background: Ceftazidime-avibactam was approved by the FDA to treat infections caused by Enterobacterales carrying blaKPC-2. However, variants of KPC-2 with amino acid substitutions at position 179 have emerged and confer resistance to ceftazidime ...
Krisztina M. Papp-Wallace, Elise T. Zeiser, Melissa D. Barnes, Robert A. Bonomo, Katherine Young, Joseph D. Rutter, Magdalena A. Taracila, Christopher R. Bethel   +7 more
core   +1 more source

Additional file 1 of Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo

, 2023
Additional file 1: Figure S1. In vivo biocompatibility of the CZA/NAC combination. (A) H&E staining images of main organs from mice after 24 h of various treatments. (B-I) Major blood cell parameters of mice after 24 h of various treatments. WBC, white blood cell; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume ...
Huang, Zeyu, Han, Yijia, Zhang, Xiaotuan, Sun, Yao, Lin, Yuzhan, Feng, Luozhu, Zhou, Tieli, Wang, Zhongyong   +7 more
openaire   +1 more source

Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae [PDF]

BMC Infectious Diseases, 2019
Carbapenem-resistant Enterobacteriaceae (CRE) represent an important global threat. The aim of this study is to describe the clinical course and outcomes of patients with CRE infections treated with ceftazidime-avibactam (CAZ-AVI) compared to patients treated with other agents.A retrospective cohort study of patients with established CRE infections ...
Basem M. Alraddadi, Mohammed Saeedi, Mohammed Qutub, Abeer Alshukairi, Ashraf Hassanien, Ghassan Wali   +5 more
openaire   +3 more sources

In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment [PDF]

, 2018
Objectives: KPC-producing Klebsiella pneumoniae (KPC-Kp) represent a serious problem worldwide. Herein, we describe the evolution of ceftazidime/avibactam resistance by sequencing longitudinal clinical isolates from a patient with KPC-Kp bloodstream ...
Andrea Berlingeri, Sara Tedeschi, Paolo Gaibani, Giannella, Maddalena, Maddalena Giannella, Silvia Lidia Volpe, Tedeschi, Sara, Bartoletti, Michele, Erika Scaltriti, Berlingeri, Andrea, Lewis, Russell E., Michele Bartoletti, Caterina Campoli, Simone Ambretti, Gaibani, Paolo, Scaltriti, Erika, Campoli, Caterina, Francesco Cristini, Pongolini, Stefano, Volpe, Silvia Lidia, Cristini, Francesco, Ambretti, Simone, Stefano Pongolini, Russell E Lewis   +23 more
core   +1 more source

In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017–2021

Journal of Global Antimicrobial Resistance, 2023
: Objectives: To report the in vitro susceptibility of Enterobacterales (n = 3905) and Pseudomonas aeruginosa (n = 1,109) isolates, collected from patients in sub-Saharan Africa (four countries) in 2017–2021, to a panel of 10 antimicrobial agents with a
Mark G. Wise, James A. Karlowsky, Meredith A. Hackel, Mohamed Amine Harti, Bontle M.E. Ntshole, Eva Njeri Njagua, Rita Oladele, Catherine Samuel, Shameema Khan, Jeannette Wadula, Warren Lowman, Busisani W. Lembede, Daniel F. Sahm   +12 more
doaj   +1 more source

Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae

, 2022
Background: Carbapenemase-producing Klebsiella pneumoniae and Escherichia coli have become a significant global health challenge. This has created an urgent need for new treatment modalities.
Frederik Boetius Hertz, Frank Hansen, Kolpen, Mette, Løbner-Olesen, Anders, Niels Frimodt-Møller, Godefroid Charbon, Frimodt-Møller, Niels, Karoline Knudsen List, Stine Radmer, Kasper Nørskov Kragh, List, Karoline Knudsen, Charbon, Godefroid, Radmer, Stine, Hertz, Frederik Boetius, Kragh, Kasper Nørskov, Hansen, Frank, Mette Kolpen, Anders Løbner-Olesen   +17 more
core   +1 more source

In vivo Selection of Imipenem Resistance Among Ceftazidime-Avibactam-Resistant, Imipenem-Susceptible Klebsiella pneumoniae Isolate With KPC-33 Carbapenemase

Frontiers in Microbiology, 2021
We describe in vivo evolution of carbapenem and ceftazidime-avibactam resistance by analyzing four longitudinal Klebsiella pneumoniae clinical isolates from a patient with pneumonia following antimicrobial treatment.
Chunlei Wang, Chunlei Wang, Chunlei Wang, Chunlei Wang, Jiankang Zhao, Jiankang Zhao, Jiankang Zhao, Jiankang Zhao, Zhibo Liu, Zhibo Liu, Zhibo Liu, Aihua Sun, Aihua Sun, Aihua Sun, Lingxiao Sun, Lingxiao Sun, Lingxiao Sun, Lingxiao Sun, Binbin Li, Binbin Li, Binbin Li, Binbin Li, Binghuai Lu, Binghuai Lu, Binghuai Lu, Binghuai Lu, Yingmei Liu, Yingmei Liu, Yingmei Liu, Yingmei Liu, Bin Cao, Bin Cao, Bin Cao, Bin Cao   +33 more
doaj   +1 more source

Table_5_Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria.docx

, 2022
Ceftazidime-avibactam is one of the last resort antimicrobial agents for the treatment of carbapenem-resistant, Gram-negative bacteria. Metallo-β-lactamase-producing bacteria are considered to be ceftazidime-avibactam resistant. Here, we evaluated a semi-
Niels Pfennigwerth (5244080), Andreas Hiergeist (3470183), Tamara Rügamer (14155239), Axel Hamprecht (605845), Yvonne Pfeifer (457305), Sören G. Gatermann (12050073), André Gessner (821452), Michaela Simon (6587036), Roman G. Gerlach (7388399), Agnes Schröder (458932), Jonathan Jantsch (458934)   +10 more
core   +1 more source

Ceftazidime-avibactam/aztreonam combination synergy against carbapenem-resistant Gram-negative isolates: In vitro study

Current Medicine Research and Practice
Background: The ceftazidime-avibactam combination is able to inhibit ESBLs, AmpCs and Class A carbapenemases and has been recommended for the treatment of complicated UTIs and ventilator-associated bacterial pneumonia.
Reena Rajan, A V Raghavendra Rao, Mathavi Suresh Kumar   +2 more
doaj   +1 more source